Validation of the French version of the London Chest Activity of Daily Living scale and the Dyspnea-12 questionnaire
Authors Beaumont M, Couturaud F, Jego F, Pichon R, Le Ber C, Péran L, Rogé C, Renault D, Narayan S, Reychler G
Received 28 June 2017
Accepted for publication 17 November 2017
Published 30 April 2018 Volume 2018:13 Pages 1399—1405
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Richard Russell
Marc Beaumont,1,2 Francis Couturaud,3 Florence Jego,4 Romain Pichon,5 Catherine Le Ber,1 Loïc Péran,1 Christophe Rogé,6 David Renault,6 Swathi Narayan,7 Gregory Reychler8–10
1Pulmonary Rehabilitation Unit, Morlaix Hospital Centre, Morlaix, France; 2European University of Occidental Brittany, EA3878, Brest, France; 3Department of Internal Medicine and Chest Diseases, EA3878 (GETBO), CIC INSERM 0502, University Hospital of Brest, European University of Occidental Brittany, Brest, France; 4Clinical Research Unit, Morlaix Hospital Centre, Morlaix, France; 5Pulmonary Rehabilitation Unit, Rennes, France; 6Pulmonology Unit, Morlaix Hospital Centre, Morlaix, France; 7European University of Occidental Brittany, Brest, France; 8Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, Brussels, Belgium; 9Service de Pneumologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium; 10Service de Médecine Physique et Réadaptation, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Introduction: Eighty percent of COPD patients experience dyspnea during activities of daily life (ADL). To the best of our knowledge, the Modified Medical Research Council (MMRC) dyspnea scale is the only validated scale designed to quantify dyspnea during ADL available in the French language. Two other instruments are only available in English versions: the London Chest Activity of Daily Living (LCADL) scale that allows a specific evaluation of dyspnea during ADL and the Dyspnea-12 questionnaire that evaluates the affective (emotional) and sensory components of dyspnea in daily life. The aim of this study was to translate and validate French versions of both LCADL and Dyspnea-12 questionnaires and to determine the reliability of these versions for the evaluation of dyspnea in severe to very severe COPD patients.
Methods: Both translation and cultural adaptation were based on Beaton’s recommendations. Fifty consecutive patients completed the French version of LCADL and Dyspnea-12 and other questionnaires (MMRC, Saint George’s Respiratory Questionnaire [SGRQ], Hospital Anxiety and Depression [HAD]), at a 2-week interval. Internal consistency, validity, and reliability of LCADL and Dyspnea-12 were evaluated.
Results: The French version of LCADL and Dyspnea-12 demonstrated good internal consistency with Cronbach’s α of, respectively, 0.84 and 0.91. LCADL was correlated significantly with item activity of SGRQ (ρ=0.55, p<0.001), total score of SGRQ (ρ=0.63, p<0.001), item impact of SGRQ (ρ=0.57, p<0.001), and HAD-depression (HAD-D) (ρ=0.47, p=0.001); and Dyspnea-12 was correlated significantly with MMRC (ρ=0.39, p<0.001), HAD-anxiety (ρ=0.64, p<0.001), and HAD-D (ρ=0.64, p<0.001). The French version of LCADL and Dyspnea-12 demonstrated good test–retest reliability with, respectively, intraclass coefficient =0.84 (p<0.001) and 0.91 (p<0.001).
Conclusion: The French versions of LCADL and Dyspnea-12 questionnaires are promising tools to evaluate dyspnea in severe to very severe COPD patients.
Keywords: COPD, dyspnea, evaluation, physiotherapy, quality of life
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]